Stoke Therapeutics, Inc. (STOK)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$29.81-0.60%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · STOK
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | |
|---|---|---|---|
| Revenues | |||
| Revenues | 27.6 | 184.4 | 36.6 |
| Total Revenues | 27.6 | 184.4 | 36.6 |
| Operating Expenses & Income | |||
| Selling, General & Admin | 82.4 | 67.1 | — |
| R&D Expenses | 168.6 | 137.9 | 89.1 |
| Operating Income | (223.4) | (20.6) | (101.4) |
| Earnings from Continuing Operations | |||
| Interest Expense | 0.0 | 0.0 | 0.0 |
| Interest & Investment Income | 14.0 | 13.8 | 12.7 |
| Other Non-Operating Income / Expenses | 14.2 | 13.7 | 12.4 |
| Net Income | |||
| Net Income | (207.9) | (6.9) | (89.0) |
| Per Share | |||
| Basic EPS | (3.15) | (0.12) | (1.65) |
| Diluted EPS | (3.15) | (0.12) | (1.65) |
| Revenue per Share | 0.42 | — | — |
| Basic Weighted Avg Shares | 66.0 | 59.2 | 54.0 |
| Diluted Weighted Avg Shares | 66.0 | 59.2 | 54.0 |
| Supplemental | |||
| EBIT | (223.4) | (20.6) | (101.4) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.